Q-omics provides the consensus-scored POM121C profile across patient tissues and cancer cell-line models. POM121C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POM121C is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, POM121C RNA expression shows 19,682 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRP, and ACC as cancer lineages where POM121C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121C survival associations across molecular data types. POM121C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121C RNA expression–survival associations across cancer types. High POM121C expression shows unfavorable associations in KICH, CESC, LGG, COAD and ACC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for POM121C RNA expression.
This table summarizes POM121C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POM121C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121C shows higher tumor expression in KIRP, KIRC, HNSC, LIHC, COAD and LUSC. The KIRP box plot shows higher POM121C RNA expression in tumor versus normal tissue (log2 FC = +1.057, t-test p < 0.001).
This table shows molecular features associated with POM121C in patient tissues and cancer cell lines. In patient samples, POM121C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POM121C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
